Form 4: Iovance Biotherapeutics CRO Equity Vesting

Chief Regulatory Officer Raj K. Puri acquired 9,766 shares of Iovance Biotherapeutics via RSU vesting, with a portion withheld for taxes.

Summary

• Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, Inc., exercised 9,766 restricted stock units (RSUs) on June 5, 2026.
• The transaction involved the vesting of RSUs, resulting in the acquisition of 9,766 shares of common stock.
• A total of 3,843 shares were withheld by the company to satisfy mandatory tax withholding obligations at a price of $4.23 per share.
• Following these transactions, the reporting person holds a total of 248,114 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine administrative filing regarding executive compensation rather than a market-moving strategic update.

Positives

• The transaction reflects the vesting of equity compensation, aligning the interests of the Chief Regulatory Officer with shareholders.

Negatives

• None identified; this is a routine equity compensation event.

Risks

• None identified; this is a standard administrative transaction related to employee compensation.

Future Outlook

The remaining restricted stock units held by the reporting person are scheduled to vest in equal quarterly installments.

Management Comments

• The transaction represents the vesting of RSUs granted on March 5, 2025.

Industry Context

StockSavvy.ai notes that this is a standard regulatory disclosure for executive equity compensation within the biotechnology sector, indicating no change in the executive's long-term commitment to the firm.

Comparison to Industry Standards

• The use of RSU vesting and mandatory tax withholding is a standard practice for executive compensation in publicly traded biotech companies.
• The transaction size is consistent with typical executive equity incentive plans for companies of similar market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Remaining RSUs will continue to vest in equal quarterly installments.

Key Dates

Keywords

Iovance Biotherapeutics, IOVA, Form 4, Insider Trading, Equity Compensation, Biotech